Datatrak's technology driven drug development (TD3) supports clinical trial industry transformation
Patient-focused models, improving adherence, and controlling costs all benefit from TD3.
Datatrak International has announced that more than 100 CROs, 10 of the top 15 pharmaceutical organizations, and 3 top 10 biotechs, are using the DATATRAK ONE UX platform in their efforts to harness technology to drive drug development.
"Technology Driven Drug Development, TD3, is the concept that underlies all technology in Datatrak's product solution portfolio. All of our customers look for every technological edge they can build into their processes. Maximizing the contribution of human and technological resources and consistently improving cost effectiveness is their daily routine. We're delighted that so many organizations are using the power of our DATATRAK ONE UX Platform to enable their success," said Laurence P. Birch, Datatrak CEO. He continued, "We're looking forward to helping the industry drive even greater efficiencies from patient-focused models, capturing big data, and using the resulting insight to increase the speed and efficacy of drug development."
Tim Lyons, Datatrak's Vice President of Product Development and Operations, stated that, "Our strategic investments in technology are moving the bar to help clinical operations capitalize on the viability of their drug pipelines. The DATATRAK ONE UX platform's capability to improve and easily configure workflows can make a huge difference as companies work to mitigate risk via adaptive trial design and risk based monitoring."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.